Medindia

X

PRA International Adds Dr. Susan Stansfield as Executive Vice President

Wednesday, September 5, 2007 General News J E 4
Advertisement
RESTON, Va., Sept. 5 PRA International(Nasdaq: PRAI), a leading clinical research organization, today announced theappointment of Dr. Susan C. Stansfield as Executive Vice President, withresponsibility for Product Registration activities in Europe, Africa andAsia-Pacific. David Dockhorn, Executive Vice President, will continue to haveresponsibility for Product Registration activities for the Americas.

"We are very pleased to continue the process of strengthening ourmanagement team with the addition of Dr. Susan Stansfield," said Terrance J.Bieker, chief executive officer of PRA International. "The appointment of anexecutive dedicated to Product Registration activities in Europe, Africa andAsia-Pacific reflects the growing scale of our international operations andthe additional opportunities we have to continue growing this part of ourbusiness. Dr. Stansfield has built an exceptional track record for managingworld-class clinical research organizations and delivering results thatincrease repeat business and attract new relationships. Dr. Stansfield sharesthe client-centric focus that is a core value of PRA, and we believe she iswell suited to take our international operations to the next level."

Dr. Stansfield has more than 20 years of experience in the clinicalresearch industry. She joins PRA International from Pharmaceutical ProductDevelopment, Inc. (PPD), where she most recently served as Senior VicePresident, Project Management and Clinical Operations, Europe. In her sixyears at PPD, Dr. Stansfield built her organization from 250 people to morethan 1,750 people operating in 50 countries, while directing the successfulexecution of client projects and developing new business opportunities. UnderDr. Stansfield's management, the European operations achieved substantialincreases in revenue, gross profit and operating margin.

Dr. Stansfield has also held senior management positions at Quintiles andInnovex, where she was responsible for business process improvement andmanaging full-service clinical research projects. Dr. Stansfield began hercareer in clinical research in various positions with the Wellcome ResearchFoundation, the Janssen Research Foundation, and Parke Davis.

Dr. Stansfield has a BSc in Physiology and Biochemistry from NottinghamUniversity and a PhD in Neuropharmacology from Reading University.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements that are subject torisks and uncertainties relating to PRA International's future financial andbusiness performance, as well as any other predictive statements that dependon future events or conditions, or that include words such as "expect,""anticipate," "intend," "plan," "believe," "seek," "may," "will," "estimate"or similar expressions of futurity. You should not place undue reliance onany forward-looking statements, which represent the company's statements onlyas of the date of this news release and are not intended to give any assuranceas to actual future events. Factors that might cause future events to differinclude: operational and personnel challenges that could result frommanagement changes; the ability to execute our strategy during managementtransitions; the ongoing need for early and late phase drug developmentservices; project cancellations and timing issues; our ability to attract andretain qualified personnel; our ability to continue providing our serviceseffectively, including the quality or accuracy of the data or reports providedand our ability to meet agreed-upon schedules; the ability and willingness ofour clients to continue to spend on research and development at ratescomparable to or greater than historical levels; trends or events affectingthe CRO industry and the demand for CRO services; government regulation,including regulatory standards applicable to CRO services; evolving ind
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Edwards Lifesciences Receives CE Mark for Edwards ...
S
Poniard Pharmaceuticals Receives FDA Fast Track De...